A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss ofFunction Mutations
Clinical Trial Grant
Administered By
Dermatology
Awarded By
Endeavor BioMedicines, Inc.
Start Date
May 8, 2023
End Date
June 1, 2026
Administered By
Dermatology
Awarded By
Endeavor BioMedicines, Inc.
Start Date
May 8, 2023
End Date
June 1, 2026